|[October 11, 2013]
Research and Markets: The U.S. Anti-Depressant Market Currently Stands at $9.4 billion in 2013 after Peaking at $12 billion in 2008
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/p35qmw/u_s)
has announced the addition of the "U.S.
Anti-Depressant Market - Old Fashion Branding Could Save The Day"
report to their offering.
At 270 million prescriptions per year, anti-depressants are the most
consumed class of therapeutics in the US. However, sales revenue does
not match prescription numbers.
The U.S. antidepressant market peaked at $12 billion in 2008, lost $2.6
billion due to expired patents during the following years and currently
stands at $9.4 billion. Over the past five years, the market has been
declining, on average, by (-4%) per year.
Currently, generics control over 40% of the market in terms of revenue
and over 85% of the market in terms of prescriptions. Any change in
price mix through adding a premium price markup for a growing brand
could re-ignite growth in the market.
randed pharmaceutical companies are increasingly pulling out the
antidepressant market, despite widespread use of the medication, as
patent expiry and new drug development failures make it unprofitable to
remain in the market.
However, according to The Pharmaceutical Strategist, the market still
holds promise for that innovative player that would manage to exact
value out of the current dissatisfaction of treatment outcome
experienced by both patients and physicians alike.
With its naturally fluctuating course, depression is a highly
placebo-responsive condition. Mean placebo response rates in
antidepressant clinical trials hover around the 35% level.
Physician-patient relationship, socio-cultural background, the treatment
situation set and setting and even the color and shape of the placebo
pill are contributing factors to the placebo response.
A dependable brand name also evokes an inherent response in the
depressed patient. With billions of dollars already invested in
developing antidepressant brands over the past two decades, finding a
way to measure such response and to reliably measure its true effect can
offer some of those valuable brands a new lease on life.
The Pharmaceutical Strategist's Strategic Consulting Reports are short
insightful quality documents targeted at product, brand, portfolio and
marketing managers in the Pharmaceutical and Medical Biotechnology
- Eli Lilly
- Forest Laboratories
For more information visit http://www.researchandmarkets.com/research/p35qmw/u_s
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]